Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06286722
Recruiting Not applicable

Optimized Rehabilitation of Older Adults With Hip Fracture and Signs of Cognitive Impairment - Feasibility Study

NCT06286722 · tracked via the Priya Life Science Denmark tracker
Sponsor
Lolland Community, Denmark
Phase
Not applicable
Started
2024-02-08
Last updated
2025-02-12

Condition(s) studied

Hip FracturesCognitive Impairment

Investigational drug(s) / intervention(s)

Progressive, individualized and structured exercise program

Progressive, individualized and structured exercise program: See description under Arms

Study summary

Older adults suffering from a hip fracture are a significant concern, with higher incidence rates among women. Mortality rates post-hip fracture are alarming, with up to 8-fold increased risk within 3 months and significant percentages within 30 days and 12 months. Older adults with hip fracture face challenges in regaining pre-fracture level of function, especially those with cognitive impairment, which affects 25% to 40% of cases and increases mortality risk. While interventions exist, such as progressive strength training and structured exercise programs, patients with hip fracture don't consistently restore pre-fracture function, particularly in cognitively impaired patients, who are often excluded from studies. Limited evidence exists on effective management for this subgroup, with a lack of clarity on community-based rehabilitation. Although guidelines suggest exercise interventions for patients with mild to moderate cognitive impairment, the specifics remain uncertain due to insufficient research focused solely on this population.

This feasibility study aims to assess the practicality and safety of implementing a 12-week individualized, progressive exercise program for older adults with hip fracture and cognitive impairment in an outpatient setting. Additionally, the investigators seek to gather qualitative insights through observations and interviews regarding participants' experiences and the perceived value of rehabilitation post-hip fracture, particularly focusing on the exercise intervention provided.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Recently (within 3 weeks) underwent surgical repair of a hip fracture (femoral neck or trochanteric fracture) * Independent pre-fracture ambulatory function (≥2 on the New Mobility Score on indoor walking) * Having signs of cognitive impairment measured with the Mini-Mental Score Examination of \<24 points, or a verified dementia diagnosis, or on information from the patient record * Living in their own home, nursing home, or assisted living facilities * Informed consent by patient Exclusion Criteria: * Pathological hip fracture * Having signs of severe dementia measured with the Mini-Mental State Examination (\<10 points) * Non-Danish speaking * Patients with an unstable health condition (e.g. not treated high blood pressure (\>180 mm HG)) evaluated by medical consultant * "Safety concerns" (e.g. underlying comorbidities that might be associated with serious adverse events) - not safe to participate in the opinion of the investigator * Having behavioral or psychotic disorders * Alcohol or drug abuse * Unable to participate in the intervention (e.g. due to blindness, no language) * Patients with any weight-bearing restrictions after surgery

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Frederiksberg Healthcare center and 24-hour rehabilitation Frederiksberg Denmark Recruiting
Stevns Healthcare Center, Stevns Municipality Hårlev Denmark Recruiting
Hørsholm Health and Rehabilitation Center Hørsholm Denmark Recruiting
Maribo Health Center, Lolland Municipality Maribo Denmark Recruiting
Guldborgsund Healthcare Center, Guldborgsund Municipality Nykøbing Falster Denmark Recruiting
Vordingborg Healthcare Center, Vordingborg Municipality Vordingborg Denmark Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06286722 on ClinicalTrials.gov ↗ ← All trials in Denmark